AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
RSV
On an individual level, it really doesn't change management all that much to test or to not test. And tests can be expensive. They can be hard to get. So a lot of times people aren't getting tested, which means we are underestimating our RSV burden compared to other viruses. We do have not a vaccine, spoilers. But we do have an interesting preventative treatment that is a monocodal antibody called palavizumab that we can use as prophylaxis for kids with certain risk factors. This is something that has good evidence can reduce severe disease and reduce hospitalization in these really high risk kids and babies.